Strontium still authorised despite an unfavourable opinion of the European Pharmacovigilance committee.
In 2014 the indications of strontium ranelate were further restricted in the European Union, and the French pharmacoeconomic committee has finally judged strontium ranelate to have "insufficient medical benefit".
D026683:Advisory Committees; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D017277:Drug Approval; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D061214:Patient Safety; D060735:Pharmacovigilance; D018570:Risk Assessment; D012307:Risk Factors; D013876:Thiophenes / Q000009:adverse effects*; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D013876:Thiophenes; C081587:strontium ranelate